Rofecoxib versus ibuprofen for acute treatment of migraine: a randomised placebo controlled trial

U K Misra, M Jose, J Kalita

METHODS

This randomised placebo controlled trial was conducted in a tertiary care teaching hospital between January 2001 and January 2002. The patients were recruited from the outpatient service of the neurology department. The protocol was approved by the institute’s ethics committee and patients gave consent to participate in the trial and fill in the headache diary. The patients had at least a 12 month history of migraine with or without aura as defined by the criteria of the International Headache Society. All the patients were over 16 years of age and none had more than six attacks of migraine per month. The patients were randomised using random number tables into three groups: rofecoxib, ibuprofen, and placebo. The randomisation was done by one investigator (JK) and the responses were evaluated by another (MJ). The blinding was done by giving identical packets containing the medication; however, the tablets were not of identical appearance. The patients were asked to maintain a headache diary and instructed to note the headache severity, functional disability, and associated symptoms such as nausea, vomiting, photophobia, and phonophobia before and after the treatment. Severity of headache and functional disability were graded on a 0–3 scale: grade 0 = normal, grade 1 = mild, grade 2 = moderate, and grade 3 = severe. Similarly functional disability was graded as 0 = normal, 1 = daily activities mildly impaired, 2 = daily activities severely impaired, and 3 = unable to perform daily activities, requiring bed rest. Patients with grade 3 functional disability needing bed rest during attacks and those with vomiting 20% or more of the time during a migraine attack were excluded. The severity of associated symptoms such as nausea, vomiting, photophobia, and phonophobia were also graded on a 0–3 scale (0 = normal, 1 = mild, 2 = moderate, and 3 = severe). A detailed clinical examination was carried out in all the patients. The patients were randomly prescribed rofecoxib 25 mg, ibuprofen 400 mg, or placebo (calcium 250 mg) kept in an identical looking packet. The patients were advised to take the study medication if headache was moderate or severe. Rescue medication (sumatriptan 100 mg or piroxicam 20 mg) was advised only after two hours, if moderate or severe headache persisted (fig 1).

Outcome was evaluated after one month or after two or more attacks, which were documented in the diary. The following three measures of efficacy were evaluated: (1) percentage of patients with grade 2 or 3 headache relief at two hours, (2) percentage of patients with grade 2 or 3 headache relief 24 hours after treatment, and (3) percentage of patients with grade 2 or 3 headache relief during the entire attack.

See end of article for authors’ affiliations

Background: Rofecoxib is a potent cyclo-oxygenase-2 inhibitor with a long duration of action. Its role in migraine has not been systematically evaluated.

Aim: To study the efficacy of rofecoxib in migraine.

Method: In a randomised placebo controlled trial rofecoxib 25 mg, ibuprofen 400 mg, and placebo were compared regarding their efficacy in relieving acute migraine attack. Migraine patients with 2–6 attacks per month were recruited. Headache severity, functional disability, and severity of associated symptoms were graded on a 0–3 scale. The primary endpoint was pain relief at two hours. Relief of associated symptoms and sustained pain relief for 24 hours were also noted.

Result: One hundred and twenty four patients were randomised into rofecoxib (42), ibuprofen (40), and placebo (42) groups. One hundred and one patients were followed up: 33 on rofecoxib, 35 ibuprofen, and 33 placebo. Patients’ ages ranged from 16–62 (mean 31.4) years, and 83 were females. Pain relief at two hours was noted in 45.5% on rofecoxib, 55.6% on ibuprofen, and 9.1% in the placebo group. The associated symptoms at two hours were reduced in 39.4% on rofecoxib, 50% on ibuprofen, and 9.1% in the placebo group. Sustained 24 hour pain relief was noted in 36.4% on rofecoxib, 41% on ibuprofen, and 6.1% in the placebo group. In the ibuprofen group, five patients had abdominal pain but there were no side effects in those on rofecoxib or in the control group. Both rofecoxib and ibuprofen were significantly effective in relieving pain, associated symptoms at two hours, and in sustained pain relief. There was no significant difference between rofecoxib and ibuprofen in aborting acute migraine attacks.

Conclusions: Both ibuprofen and rofecoxib were superior to placebo in aborting an acute migraine attack, and there was no significant difference in their efficacy in an acute migraine attack.

Abbreviations: CI, confidence interval; COX, cyclo-oxygenase; OR, odds ratio
patients with pain relief at two hours, (2) percentage of patients free of associated symptoms—that is, absence of nausea, vomiting, photophobia, or phonophobia, and (3) percentage of patients with 24 hours of sustained pain relief—that is, absence of recurrence of headache and lack of requirement of antimigraine medication for 24 hours. Headache recurrence was defined as the recurrence of moderate to severe headache within 24 hours of dosing in patients who initially had relief of pain two hours after medication. Any side effects of the drugs up to 24 hours after ingestion were also noted.

This study was designed as a non-inferiority trial expecting rofecoxib to be as good as ibuprofen and superior to placebo. In order to detect the difference between the two drugs alpha risk was taken as 5%, critical difference in the drugs was taken as 10%, and the power calculation was done according to the method described by Agresti.\(^1\) Sample size was based on the response rate. Pain relief at two hours was considered important (efficacy of the drug) and the standard deviation was taken as ±2. Based on this criterion the sample size was calculated to be at least 30 in each group. The effect of treatment—that is, percentage of patients with 24 hour pain relief, percentage of patients free of associated symptoms, and percentage of patients with pain relief at 24 hours—was studied by logistic regression analysis. Comparison of two proportions at a time was done using the Z test of proportion.

**RESULTS**

One hundred and twenty four patients with migraine who fulfilled the inclusion criteria were recruited. Altogether 101 were followed up and 23 lost to follow up. The age of the patients ranged from 16–62 (mean 32.3) years and 83 were females. The monthly headache frequency ranged from two to six, and headache duration ranged from 4–36 hours. Sleep and analgesics were relieving factors in 98% patients. There was no baseline difference in the severity of headache in the three groups. Before medication, headache was severe in 82% patients. Associated symptoms such as nausea were present in all, vomiting in 89%, and photophobia and phonophobia in 99% of the patients. Vomiting in these patients, however, did not exceed 20% of the time of the migraine attack.

**Efficacy analysis**

In the 101 patients included in this study, active drugs more frequently aborted the migraine attack compared with placebo at two hours. In the rofecoxib group 45.5% of the patients were relieved of pain and 39.4% were free of associated symptoms at two hours. In the ibuprofen group 55.6% patients were relieved of pain and 50% were free of associated symptoms, while in the placebo group it was 9.1% for both measures. In the rofecoxib group, sustained pain relief was present in 36.4% patients, in the ibuprofen group 41.7%, and in control group only 6.1%. Two hour pain relief was significantly superior in rofecoxib (odds ratio (OR) 8.33, 95% confidence interval (CI) 2.12 to 32.65, power 0.83) and ibuprofen (OR 12.50, 95% CI 3.22 to 48.55, power 0.82) compared with placebo. In relieving associated symptoms rofecoxib (OR 6.5, 95% CI 1.64 to 25.76, power 0.83) and ibuprofen (OR 10.0, 95% CI 2.57 to 38.76, power 0.82) were significantly superior to placebo. Twenty four hour sustained pain relief was also significantly better in rofecoxib (OR 8.86, 95% CI 1.79 to 43.71, power 0.81) and ibuprofen (OR 11.07, 95% CI 2.29 to 53.54, power 0.81) compared with placebo. On comparing the efficacy of ibuprofen and rofecoxib by Z test there was no significant difference in their ability to relieve pain at two hours (Z = 0.84, p = 0.20), relief of associated symptoms (Z = 0.88, p = 0.19), and 24 hour pain relief (Z = 0.45, p = 0.33). Rofecoxib and ibuprofen were significantly effective in relieving pain at two hours (rofecoxib Z 3.32, p = 0.0005; ibuprofen Z = 4.09, p = 0.000002); relief of associated symptoms (rofecoxib Z = 2.87, p = 0.002; ibuprofen Z = 3.69, p = 0.0001); and 24 hour sustained pain relief (rofecoxib Z = 3.01, p = 0.001; ibuprofen Z = 3.42, p = 0.0003). The patients in the rofecoxib group did not experience any side effects whereas five patients in the ibuprofen group experienced abdominal pain, which was severe in one. The response to various drugs is shown in fig. 2.
DENCE of gastric ulcers, as evaluated by endoscopy, compared
antinociceptive systems in the brainstem.17 18
analgesic effect or more specific effect on the trigeminal and
vessels.16 Ibuprofen may inhibit the COX system, resulting in
dural venule. It also results in degranulation of mast cells,
and calcitonin gene related peptides—that results in dilata-
tion of arteries.14 15
There is also release of vasoactive peptides—neurokinin A
is aseptic inflammation in the trigeminovascular system.14 15
the basis of reported efficacy of these drugs in osteo-
arthritis.7–9 Ibuprofen in the dose of 400, 800, and 1200 mg
was proven to be more effective than placebo and com-
parable to 15 mg/kg paracetamol in children.7–9 Rofecoxib
was proven to be more effective than placebo and com-
bined 12.5–25 mg daily was as effective as ibuprofen 800 mg thrice
daily for six weeks and diclofenac sodium 50 mg thrice daily for
6–12 months in arthritis.9
The basis of efficacy and gastrointestinal safety of rofecoxib
is attributed to its mechanism of action. Prostaglandins are formed
by the interaction of COX-1 and COX-2. COX-1 is present mainly in gastric mucosa, kidney, and platelets.
COX-2 is mainly an inducible form and present constitutively
to some extent in the central nervous system, placenta, and
the juxtaglomerular apparatus of the kidney. Both isofoms
contribute to the inflammatory process but COX-2 is of
special interest as it is induced by inflammation. Ibuprofen
inhibits both the isoforms to a similar extent. COX-2 inhibitors are 100–1000 times more selective on COX-2
than COX-1, which is maintained even at a much higher
dosage.16 Rofecoxib has been found to have a lower incid-
ence of gastric ulcers, as evaluated by endoscopy, compared with ibuprofen14 and naproxen.15 However, the gastroin-
testinal safety of rofecoxib has been questioned by some
investigators.15
The efficacy of COX-1 and COX-2 inhibitors in migraine
may be due to an anti-inflammatory effect. In migraine, there is
aseptic inflammation in the trigeminovascular system.14 15
There is also release of vasoactive peptides—neurokinin A
and calcitonin gene related peptides—that results in dilata-
tion of vessels and leakage of albumin from blood vessels.
None of these peptides is capable of disrupting the blood-
brain barrier. These neupeptides also initiate the events
resulting in formation of endothelial microvilli, endothelial
vesicles, and vacuoles especially within the postcapillary
dural venule. It also results in degranulation of mast cells,
platelet aggregation, and leakage of plasma from meningeal
vessels.15 Ibuprofen may inhibit the COX system, resulting in
relief of pain. The other possible mechanisms may include its
analgesic effect or more specific effect on the trigeminal and
antinociceptive systems in the brainstem.17 18
We have excluded patients with very frequent migraine
attacks because they are not suitable for drug trials on an
outpatient basis. Similarly patients with frequent vomiting
exceeding 20% of the duration of an attack have been excluded
because vomiting may interfere with drug absorption. In our
study 22 patients were lost to follow up. The clinical
characteristics—that is, age, sex, severity of pain, and associated
symptoms—of the patients who were lost to follow up were not
significantly different from the study group. There was no
protocol deviation. The pain relief in our study was based on
subjective evaluation by the patient, which is an inherent
limitation of such studies. Our patients received identical drug
packets, although the appearance of the drugs was not similar.
This could have introduced a bias in a crossover study. We,
however, did not follow a crossover design. While it is unlikely
that the difference in tablets would create bias in a non-
crossover study, it could be argued that patients at follow up
could allude to the colour or size of a tablet, which effectively
would unblind the observer. However, the observer was largely
collating results from the patients’ diaries; therefore, this source
of potential bias is unlikely to be important.

The reported efficacy of ibuprofen in migraine is 42%–
72%.7–9 19 20 The response rate of ibuprofen in our study was
55.6%. Ibuprofen is regarded as a relatively safe drug with
good tolerance.7–9 19 20 Only five patients in our study who were
on ibuprofen therapy had pain in the abdomen; this was
severe in one patient only. However, in the rofecoxib group,
no side effects were noted, which is in agreement with the
superior safety profile of rofecoxib.21 22
The lower frequency of gastrointestinal side effects in the
rofecoxib group is an advantage but in the ibuprofen group
side effects were not serious. It seems logical to avoid ibupro-
fen in a patient with a history of acid peptic disease and in
these patients, rofecoxib may be preferred over ibuprofen.

ACKNOWLEDGEMENTS
The authors thank Dr S K Mandal for statistical analysis and Rakesh
Kumar Nigam for secretarial help.

Authors’ affiliations
U K Misra, M Jose, J Kalita, Department of Neurology, Sanjay Gandhi
Post Graduate Institute of Medical Sciences, Lucknow, India

REFERENCES
2 Matheson AJ, Figgitt DP. Rofecoxib: a review of its use in the management of
3 Headache Classification Committee of the International Headache Society. A
classification and diagnostic criteria for headache disorders, cranial
4 Adedjou MJ, Lipton RB, Ferran MD, et al. Comparison of non-steroidal anti-
inflammatory drugs and triplets on stringent measures of efficacy. Neurology
6 Cashwell J, Holt P, MK 0966, a specific COX 2 inhibitor, has clinical efficacy
comprollable to diclofenac in the treatment of knee and hip osteoarthritis (OA)
7 Hamalainen ML, Happu K, Valkila E, et al. Ibuprofen or acetaminophen for
the acute treatment of migraine in children: a double-blind, randomized,
8 Havako-Kannianen H. Treatment of acute migraine attack: ibuprofen and
9 Kolster R, Nistvold K, Vilming S. A double-blind study of ibuprofen versus
10 Everts B, Wahlborg P, Kedren T. Cox 2 specific inhibitors—the emergence of
11 Laive L, Harper S, Simon T, et al. For the rofex Cox 2 endoscopy study group. A randomized trial comparing the effect of rofex Cox 2, a
cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the
gastrointestinal mucosa of patients with osteoarthritis. Gastroenterology
12 Hawkey CJ, Laive L, Simon T, et al. On behalf of the Rofex Cox, Rheumatoid Arthritis
Endoscopy Study Group, et al. Incidence of gastrointestinal ulcers in patients
with rheumatoid arthritis after 12 weeks of rofex Cox, naproxen or placebo: a
13 Juni P, Rutjes AWS, Dieppe PA. Are selective COX II inhibitors superior to
14 Welch NK, Cutler FM, Goodby PJ. Migraine pathogenesis: neural and
15 Moskowitz MA. Basic mechanisms in vascular headache. Neural Clin


IMAGES IN MEDICINE

Flecainide challenge test for the diagnosis of Brugada syndrome

A 52 year old white man presented having woken up feeling dizzy and unwell. He went to the bathroom and on returning to his bedroom he lost consciousness. He came around spontaneously with no evidence of neurological deficit. He did not have any palpitations. His initial electrocardiogram (ECG) showed 2 mm ST elevation in V2 only (fig 1). The ST elevation in the right side of the precordial leads was associated with a partial right bundle branch block pattern and varied spontaneously over time. There was no evidence of an acute coronary syndrome. We then performed an intravenous flecainide challenge. His baseline ECG showed minor concave ST elevation in V2 only but then he went on to develop classical Brugada changes with a maximum of 5 mm ST elevation in V2 associated with T wave inversion (fig 2). No arrhythmia was provoked. Coronary angiography was normal and he was fitted with an implantable cardioverter defibrillator. Brugada syndrome is characterised by marked ST-segment elevation in the right precordial ECG leads (unrelated to ischaemia, electrolyte abnormalities, or structural heart disease) with a morphology of the QRS complex resembling a right bundle branch block, and is associated with a high risk for sudden death. The mechanisms responsible for the electrocardiographic actions of class 1 antiarrhythmic agents in Brugada syndrome are thought to be due to their ability to block sodium channels. Strong sodium channel blockade facilitates the loss of the right ventricular epicardial plateau phase by altering the balance of current at the end of phase 1 of the action potential from inward to outward. The result is an all or nothing repolarisation of the right ventricular action potential and marked abbreviation of the epicardial action potential duration. The loss of the plateau in right ventricular epicardium but not endocardium creates a transmural voltage gradient that manifests as an ST-segment elevation in the right precordial leads of the ECG.

![Figure 1 Initial ECG.](image1)

![Figure 2 ECG showing classical Brugada changes.](image2)

Correspondence to: Dr Manas K Sinha, Department of Cardiology, Atkinson Morley Wing, St George’s Hospital, Blackshaw Road, London SW17 0QT, UK; msinha@sghms.ac.uk

REFERENCES


Rofecoxib versus ibuprofen for acute treatment of migraine: a randomised placebo controlled trial

U K Misra, M Jose and J Kalita

Postgrad Med J 2004 80: 720-723
doi: 10.1136/pgmj.2003.012393

Updated information and services can be found at:
http://pmj.bmj.com/content/80/950/720

These include:

References
This article cites 19 articles, 4 of which you can access for free at:
http://pmj.bmj.com/content/80/950/720#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Headache (including migraine) (33)
- Pain (anaesthesia) (10)
- Pain (neurology) (231)
- Pain (palliative care) (14)
- Epidemiology (401)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/